← Back to Search

ED-LINC for Opioid Use Disorder (ED-LINC2 Trial)

N/A
Recruiting
Led By Lauren K Whiteside, MD, MS
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline ed visit and 1, 3, 6 and 12-months after ed visit
Awards & highlights

ED-LINC2 Trial Summary

This trial is testing a new way of delivering healthcare targeting behavioral health or substance abuse that has shown promise in earlier studies. The team is testing whether this new way (ED-LINC) is more effective than usual care in reducing self-reported illicit opioid use, increasing use of medications for opioid abuse disorder, and reducing emergency department utilization.

Who is the study for?
This trial is for adults over 18 with moderate or severe opioid use disorder (OUD) who have a phone and can provide contact information. It's not for those in other care programs, incarcerated individuals, non-English speakers, people living far from Harborview Medical Center, or patients needing urgent psychiatric help.Check my eligibility
What is being tested?
The study tests 'Emergency Department Longitudinal Integrated Care' (ED-LINC), which aims to improve outcomes for OUD patients. It compares ED-LINC's effectiveness against usual care in reducing illicit opioid use, increasing treatment retention, and decreasing emergency department visits.See study design
What are the potential side effects?
Since the intervention involves healthcare delivery rather than medication, typical drug side effects are not expected. However, participants may experience stress or discomfort related to changes in their care routine.

ED-LINC2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

ED-LINC2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline ed visit and 1, 3, 6 and 12-months after ed visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline ed visit and 1, 3, 6 and 12-months after ed visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Emergency Department visits
Change in Illicit Opioid Use Over Time
Initiation of Medications for OUD
Secondary outcome measures
Engagement in Medications for OUD
Intervention effect by sex
Intervention effect when associated PTSD
+8 more

ED-LINC2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ED-LINC InterventionExperimental Treatment1 Intervention
Patients assigned to the ED-LINC intervention will receive 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
Group II: Usual CareActive Control1 Intervention
Participants assigned to this arm will receive usual care.

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,732 Previous Clinical Trials
1,841,452 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,455 Previous Clinical Trials
2,596,464 Total Patients Enrolled
Lauren K Whiteside, MD, MSPrincipal InvestigatorUniversity of Washington

Media Library

ED-LINC Clinical Trial Eligibility Overview. Trial Name: NCT05327166 — N/A
Opioid Use Disorder Research Study Groups: Usual Care, ED-LINC Intervention
Opioid Use Disorder Clinical Trial 2023: ED-LINC Highlights & Side Effects. Trial Name: NCT05327166 — N/A
ED-LINC 2023 Treatment Timeline for Medical Study. Trial Name: NCT05327166 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objectives have been set for completion of this trial?

"This trial's primary purpose, which will be assessed at baseline and 1, 3, 6, and 12 months post-ED visit is to initiate medications for OUD. Subordinate aims include evaluating the effects of methamphetamine use (as measured by timeline follow-back) on the intervention’s outcomes; exploring how anxiety impacts outcome results; as well as tracking engagement in MOUD - including buprenorphine, methadone & naltexone – over a year after index ED visitation through state data regarding prescriptions/medication administrations combined with patient self-reporting."

Answered by AI

Does this trial currently have openings for participants?

"Yes, the latest information from clinicaltrials.gov suggests that this medical trial is recruiting participants - it was initially posted on April 12th 2022 and amended as recently as May 13th 2022. It requires 500 individuals to be sourced from a single site."

Answered by AI

How many participants are currently involved in this experiment?

"Affirmative. According to clinicaltrials.gov, this trial is recruiting now, with the initial posting of April 12th 2022 and last update on May 13th 2022. The study will involve 500 subjects at one medical centre."

Answered by AI

Who else is applying?

What site did they apply to?
Harborview Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+
~260 spots leftby Apr 2026